Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Endogenous ligands of benzodiazepine binding site have inverse agonistic properties

Jiri Sliva, Ladislav Hess, Martin Votava, Jiri Malek

. 2013 ; 81 (6) : 1075-1077.

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc14074549

Grantová podpora
NT11284 MZ0 CEP - Centrální evidence projektů

Benzodiazepines have been widely used in clinical praxis for many decades. They act as GABAA receptor agonists and possess muscle-relaxant, hypnotic-sedative, anticonvulsant, and anxiolytic properties. Flumazenil acts as a benzodiazepine receptor antagonist (subunits α1, α2, α3, and α5) or partial agonist (subunits α4 and α6). It competitively inhibits the activity at the benzodiazepine recognition site on the GABA/benzodiazepine receptor complex, thereby reversing the effects of benzodiazepines. In our experiments, administration of flumazenil in rabbits was surprisingly associated with anxiolytic effects similar to those of midazolam. Additionally, flumazenil significantly and dose-dependently decreased the total number of vocalizations in rats, i.e. it was anxiolytic. These observations seem to be in contrast to the effect of flumazenil in humans, where it is believed to produce mainly anxiogenic effects. It seems that in individuals, who exhibit anxiogenic behavior or in individuals with anticipation anxiety, flumazenil acts as an anxiolytic agent, while in individuals without any signs of anxiety, flumazenil can also act as anxiogenic agent. Thus, we hypothesize that flumazenil is associated with decreased intensity of anticipatory anxiety due to occupancy of benzodiazepine binding sites by an endogenous ligand with inverse agonistic properties.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc14074549
003      
CZ-PrNML
005      
20150112124449.0
007      
ta
008      
141006s2013 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.mehy.2013.10.006 $2 doi
035    __
$a (PubMed)24183322
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Sliva, Jiri $u Department of Pharmacology, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic; Department of Pharmacology, 3rd Faculty of Medicine, Charles University, Prague, Czech Republic. Electronic address: jiri.sliva@lfmotol.cuni.cz.
245    10
$a Endogenous ligands of benzodiazepine binding site have inverse agonistic properties / $c Jiri Sliva, Ladislav Hess, Martin Votava, Jiri Malek
520    9_
$a Benzodiazepines have been widely used in clinical praxis for many decades. They act as GABAA receptor agonists and possess muscle-relaxant, hypnotic-sedative, anticonvulsant, and anxiolytic properties. Flumazenil acts as a benzodiazepine receptor antagonist (subunits α1, α2, α3, and α5) or partial agonist (subunits α4 and α6). It competitively inhibits the activity at the benzodiazepine recognition site on the GABA/benzodiazepine receptor complex, thereby reversing the effects of benzodiazepines. In our experiments, administration of flumazenil in rabbits was surprisingly associated with anxiolytic effects similar to those of midazolam. Additionally, flumazenil significantly and dose-dependently decreased the total number of vocalizations in rats, i.e. it was anxiolytic. These observations seem to be in contrast to the effect of flumazenil in humans, where it is believed to produce mainly anxiogenic effects. It seems that in individuals, who exhibit anxiogenic behavior or in individuals with anticipation anxiety, flumazenil acts as an anxiolytic agent, while in individuals without any signs of anxiety, flumazenil can also act as anxiogenic agent. Thus, we hypothesize that flumazenil is associated with decreased intensity of anticipatory anxiety due to occupancy of benzodiazepine binding sites by an endogenous ligand with inverse agonistic properties.
650    _2
$a zvířata $7 D000818
650    _2
$a anxiolytika $x aplikace a dávkování $x farmakologie $7 D014151
650    _2
$a úzkost $x farmakoterapie $7 D001007
650    _2
$a benzodiazepiny $x antagonisté a inhibitory $x metabolismus $7 D001569
650    _2
$a vazebná místa $7 D001665
650    _2
$a flumazenil $x aplikace a dávkování $x farmakologie $7 D005442
650    _2
$a antagonisté receptorů GABA-A $x aplikace a dávkování $x farmakologie $7 D058787
650    _2
$a lidé $7 D006801
650    _2
$a ligandy $7 D008024
650    12
$a biologické modely $7 D008954
650    _2
$a králíci $7 D011817
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Hess, Ladislav $u Institute for Clinical and Experimental Medicine, Laboratory of Experimental Anaesthesiology, Prague, Czech Republic
700    1_
$a Votava, Martin $u Department of Pharmacology, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Malek, Jiri $u Department of Pharmacology, 3rd Faculty of Medicine, Charles University, Prague, Czech Republic
773    0_
$w MED00003234 $t Medical hypotheses $x 1532-2777 $g Roč. 81, č. 6 (2013), s. 1075-1077
856    41
$u https://pubmed.ncbi.nlm.nih.gov/24183322 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20141006 $b ABA008
991    __
$a 20150112124629 $b ABA008
999    __
$a ok $b bmc $g 1042432 $s 873461
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2013 $b 81 $c 6 $d 1075-1077 $i 1532-2777 $m Medical hypotheses $n Med Hypotheses $x MED00003234
GRA    __
$a NT11284 $p MZ0
LZP    __
$a Pubmed-20141006
Zpět

Najít záznam

Citační ukazatele

Možnosti archivace